Evidence map›Paper›PMID 39497832›Full record

ArticleFrontiers in immunology2024

Activating

Katharine B Moosic, Thomas L Olson, Mark Freijat, Samara Khalique, Cait E Hamele, Bryna Shemo, Jesse Boodoo, William Baker, Gitanjali Khurana, Matthew Schmachtenberg and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Katharine B MoosicUniversity of Virginia Cancer Center, University of Virginia School of Medicine, Charlottesville, VA, United States.
Thomas L OlsonUniversity of Virginia Cancer Center, University of Virginia School of Medicine, Charlottesville, VA, United States.
Mark FreijatDivision of Rheumatology, Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA, United States.
Samara KhaliqueDivision of Rheumatology, Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA, United States.
Cait E HameleUniversity of Virginia Cancer Center, University of Virginia School of Medicine, Charlottesville, VA, United States.
Bryna ShemoUniversity of Virginia Cancer Center, University of Virginia School of Medicine, Charlottesville, VA, United States.
Jesse BoodooDivision of Rheumatology, Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA, United States.
William BakerDivision of Rheumatology, Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA, United States.
Gitanjali KhuranaDivision of Rheumatology, Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA, United States.
Matthew SchmachtenbergUniversity of Virginia Cancer Center, University of Virginia School of Medicine, Charlottesville, VA, United States.
Tristin DuffyUniversity of Virginia Cancer Center, University of Virginia School of Medicine, Charlottesville, VA, United States.
Aakrosh RatanUniversity of Virginia Cancer Center, University of Virginia School of Medicine, Charlottesville, VA, United States.
Erika DarrahDivision of Rheumatology, The Johns Hopkins School of Medicine, Baltimore, MD, United States.
Felipe AndradeDivision of Rheumatology, The Johns Hopkins School of Medicine, Baltimore, MD, United States.
Marieke JonesDepartment of Public Health Sciences, School of Medicine, University of Virginia, Charlottesville, VA, United States.
Kristine C OlsonUniversity of Virginia Cancer Center, University of Virginia School of Medicine, Charlottesville, VA, United States.
David J FeithUniversity of Virginia Cancer Center, University of Virginia School of Medicine, Charlottesville, VA, United States.
Donald L KimpelDivision of Rheumatology, Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA, United States.
Thomas P LoughranUniversity of Virginia Cancer Center, University of Virginia School of Medicine, Charlottesville, VA, United States.

Funding

Cancer Research Training Program: From Molecular Mechanisms to Therapeutic StrategiesT32CA009109 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Andrew Carl Dudley, Melanie R Rutkowski · 1985 to 2026
$13.9M
Genomic Architecture of LGL LeukemiaR01CA178393 · NCI · UNIVERSITY OF VIRGINIA · PI Thomas P. Loughran, Aakrosh Ratan · 2016 to 2026
$6.5M
The role of cytotoxic T cells in rheumatoid arthritis pathogenesisR01AR079404 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI ANDRADE, FELIPE · 2021 to 2025
$2.9M
NCI NIH HHS R01 CA178393NCI NIH HHS T32 CA009109NIAMS NIH HHS R01 AR079404
6 · The paper itself

Abstract

Objectives: Large granular lymphocyte (LGL) leukemia is a rare hematologic malignancy characterized by clonal expansion of cytotoxic T-cells frequent somatic activating Methods: Blood samples, clinical parameters, and demographics were collected from 98 RA patients and 9 healthy controls (HCs). CD8+ cell DNA was isolated and analyzed via droplet digital (dd)PCR to detect Results: RA patients had significantly increased presence of Conclusions:

Indexed as

Arthritis, RheumatoidCD8-Positive T-LymphocytesMutationSTAT3 Transcription FactorAdultAgedFemaleGene FrequencyHumansLeukemia, Large Granular LymphocyticMaleMiddle AgedSTAT3 protein, humanSTAT3 Transcription Factoranti-citrullinated protein antibodiesCD8-positive T-lymphocytesJAK/STATlarge granular lymphocytic leukemiarheumatoid arthritisrheumatoid factorstat3

Identifiers

PMID39497832
PMCPMC11532115

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.